Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

CROs can contribute to site collaboration by also identifying and supporting non-academic institutions capable of conducting ...

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

INmune Bio (NASDAQ:INMB) announced a partnership with the Cell and Gene Therapy Catapult, a UK-based innovation center ...

Following CORDStrom TM, INmune Bio plans to transition production of INKmune ®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and ...

Feb. 7, 2025 — A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 ...

Cell and gene therapy manufacturers that adopt automated bioprocessing technologies are likely to use AI in QA/QC and batch release.

INmune Bio (INMB) has partnered with the Cell and Gene Therapy Catapult to establish large-scale, commercial-ready manufacturing for its cell ...

CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with ...